ADMINISTRATIVE CORE, CENTER DIRECTOR, ENRICHMENT PROGRAM

行政核心、中心主任、浓缩计划

基本信息

  • 批准号:
    8015122
  • 负责人:
  • 金额:
    $ 78.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

Overview Understanding the pathogenesis of Inflammatory Bowel Diseases (IBD) represents one of the most important and unresolved challenges in both clinical and investigative digestive diseases. As a result of research advances over the past several years, including many made possible by this Center, it is now possible to formulate a central hypothesis for the pathogenesis of these disorders and to apply powerful new tools that will facilitate further advances in the next several years. The many novel aspects of our understanding of the multiple pathwavs to ulcerative colitis (UC) and Crohn's disease (CD) are based upon a comprehensive dissection of the manv complexities of mucosal biology. These advances are also based on knowledge of factors sustaining surface epithelial integrity, innate immunity, lymphocyte activation, host-microbe interaction, genetic architecture of Crohn's disease and ulcerative colitis, and functional characterization of lymphocytes and antigen presenting cell populations in the intestinal mucosa. Since the last competing application, the participating collaborating investigators in this Center for the Study of IBD (CSIBD) have made many key advances in the understanding of the processes relevant to IBD and catalyzed by CSIBD, have increased their research support. The CSIBD has achieved its original goals, primarily by expanding the infrastructural support available to a cohort of highly productive investigators, and by offering, through the awarding of pilot feasibility grants, opportunities for the initiation of new ventures in inflammatory bowel disease-related research aimed primarily at young investigators. The current proposal reflects the conviction of members of the research community at the Massachusetts General Hospital (MGH), the Beth Israel Deaconess Medical Center (BIDMC), the Massachusetts Institute of Technology (MIT), the Broad Institute of Harvard and MIT and the Tufts University Medical Center that they remain in an outstanding position to achieve integration of a broad base of investigators who study basic processes of innate and adaptive immune responses, inflammatory mediators, epithelial cell function and mucosal-microbial interaction. Specifically, Center investigators are well-positioned in the coming period to undertake novel approaches, as the CSIBD has recently initiated a collaboration with the Broad Institute that will allow CSIBD investigators access to a wide array of Broad research platforms in addition to Core services. The need for Pilot Feasibility Support (PFS) by the Boston-Cambridge IBD research communities is unabated, as evidenced by the number of applications per cycle. The Center Centers have been upgraded to offer stateof-the-art computational tools and bioinformatics support, in the coming period. Gene chip technology has now moved on from microarray to so-called deep sequencing which will be offered in the Genetics, Genomics and Molecular Biology Core both in the MGH setting and for selected projects at the Broad Institute Platform. A major focus of the next funding period will be the clinical translation of human genetics research to understand biological predisposition, to dissect biological pathways that mark disease and identify targets for drug intervention. Investigators are exploring alterations of these processes in both animal models of intestinal inflammation as well as in patients with IBD. We believe that this Center for the Study of Inflammatory Bowel Disease (CSIBD) will continue to provide a highly effective framework for promoting these interactions and a mechanism for the interface of the research community with both powerful new tools for IBD research and a large clinical investigation, patient and tissue base.
概述

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ramnik J Xavier其他文献

MIT Open Access Articles Gene networks that compensate for crosstalk with crosstalk
麻省理工学院开放获取文章用串扰补偿串扰的基因网络
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Springer Science;Business Media;Isaak E. Müller;Jacob R. Rubens;Tomi Jun;Daniel Graham;Ramnik J Xavier;Timothy K. Lu
  • 通讯作者:
    Timothy K. Lu

Ramnik J Xavier的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ramnik J Xavier', 18)}}的其他基金

Cardiovascular disease, metabolic syndrome, microbes and metabolites in FHS
FHS 中的心血管疾病、代谢综合征、微生物和代谢物
  • 批准号:
    10367105
  • 财政年份:
    2022
  • 资助金额:
    $ 78.38万
  • 项目类别:
Cardiovascular disease, metabolic syndrome, microbes and metabolites in FHS
FHS 中的心血管疾病、代谢综合征、微生物和代谢物
  • 批准号:
    10556439
  • 财政年份:
    2022
  • 资助金额:
    $ 78.38万
  • 项目类别:
Core 2: Immune Bioinformatics and Computational Biology Core
核心2:免疫生物信息学和计算生物学核心
  • 批准号:
    10251175
  • 财政年份:
    2019
  • 资助金额:
    $ 78.38万
  • 项目类别:
Core 2: Immune Bioinformatics and Computational Biology Core
核心2:免疫生物信息学和计算生物学核心
  • 批准号:
    10020930
  • 财政年份:
    2019
  • 资助金额:
    $ 78.38万
  • 项目类别:
RP2: Targeting genes and pathways for autophagy-dependent inhibition of bacterial infection
RP2:自噬依赖性抑制细菌感染的靶向基因和途径
  • 批准号:
    10364724
  • 财政年份:
    2019
  • 资助金额:
    $ 78.38万
  • 项目类别:
RP2: Targeting genes and pathways for autophagy-dependent inhibition of bacterial infection
RP2:自噬依赖性抑制细菌感染的靶向基因和途径
  • 批准号:
    10573259
  • 财政年份:
    2019
  • 资助金额:
    $ 78.38万
  • 项目类别:
Functional characterization of CARD9 genetic variants in fungal immunity
CARD9 遗传变异在真菌免疫中的功能表征
  • 批准号:
    10331807
  • 财政年份:
    2018
  • 资助金额:
    $ 78.38万
  • 项目类别:
Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital
马萨诸塞州总医院炎症性肠病研究中心
  • 批准号:
    9262326
  • 财政年份:
    2016
  • 资助金额:
    $ 78.38万
  • 项目类别:
Bacterial Dysbiosis in IgG4-RD
IgG4-RD 中的细菌生态失调
  • 批准号:
    8732925
  • 财政年份:
    2014
  • 资助金额:
    $ 78.38万
  • 项目类别:
ATG16L1 T300A: genetics to biology
ATG16L1 T300A:遗传学到生物学
  • 批准号:
    8588317
  • 财政年份:
    2013
  • 资助金额:
    $ 78.38万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 78.38万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 78.38万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 78.38万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 78.38万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 78.38万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 78.38万
  • 项目类别:
    Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 78.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 78.38万
  • 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 78.38万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 78.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了